Squar Milner Financial Services LLC Boosts Position in Becton Dickinson and Co (NYSE:BDX)

Squar Milner Financial Services LLC raised its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 11.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,932 shares of the medical instruments supplier’s stock after buying an additional 201 shares during the quarter. Squar Milner Financial Services LLC’s holdings in Becton Dickinson and were worth $488,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of BDX. Whittier Trust Co. grew its holdings in shares of Becton Dickinson and by 0.6% during the second quarter. Whittier Trust Co. now owns 6,982 shares of the medical instruments supplier’s stock worth $1,760,000 after purchasing an additional 40 shares in the last quarter. ProVise Management Group LLC grew its holdings in shares of Becton Dickinson and by 2.2% during the second quarter. ProVise Management Group LLC now owns 1,902 shares of the medical instruments supplier’s stock worth $479,000 after purchasing an additional 41 shares in the last quarter. Pitcairn Co. grew its holdings in shares of Becton Dickinson and by 1.3% during the second quarter. Pitcairn Co. now owns 3,227 shares of the medical instruments supplier’s stock worth $813,000 after purchasing an additional 41 shares in the last quarter. Ropes Wealth Advisors LLC grew its holdings in shares of Becton Dickinson and by 0.6% during the second quarter. Ropes Wealth Advisors LLC now owns 6,801 shares of the medical instruments supplier’s stock worth $1,714,000 after purchasing an additional 43 shares in the last quarter. Finally, Armor Investment Advisors LLC grew its holdings in shares of Becton Dickinson and by 0.5% during the second quarter. Armor Investment Advisors LLC now owns 9,265 shares of the medical instruments supplier’s stock worth $2,335,000 after purchasing an additional 44 shares in the last quarter. 84.26% of the stock is owned by institutional investors and hedge funds.

NYSE:BDX traded up $1.06 during mid-day trading on Wednesday, reaching $251.34. The stock had a trading volume of 584,893 shares, compared to its average volume of 917,113. The firm has a 50 day moving average price of $254.41 and a two-hundred day moving average price of $246.27. The stock has a market capitalization of $68.60 billion, a P/E ratio of 22.83, a P/E/G ratio of 1.63 and a beta of 1.12. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $264.74. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.05 by $0.03. The company had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.37 billion. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. Becton Dickinson and’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.91 EPS. Research analysts forecast that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,532 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the sale, the chief executive officer now owns 218,671 shares in the company, valued at $56,937,554.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Charles R. Bodner sold 1,514 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $260.08, for a total value of $393,761.12. Following the completion of the sale, the senior vice president now owns 5,180 shares of the company’s stock, valued at approximately $1,347,214.40. The disclosure for this sale can be found here. Insiders sold a total of 37,249 shares of company stock valued at $9,616,803 in the last 90 days. 0.12% of the stock is currently owned by corporate insiders.

BDX has been the subject of several recent analyst reports. Morgan Stanley boosted their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. Wells Fargo & Co boosted their price objective on Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Raymond James boosted their price objective on Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a report on Friday, June 28th. Piper Jaffray Companies cut their price objective on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $266.55.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Hedge Funds – How They Work For Investors

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.